In vivo correction of murine tyrosinemia type I by DNA-mediated transposition

Eugenio Montini, Patrice K. Held, Meenakshi Noll, Nicolas Morcinek, Muhsen Al-Dhalimy, Milton Finegold, Stephen R. Yant, Mark A. Kay, Markus Grompe

Research output: Contribution to journalArticle

124 Scopus citations

Abstract

Gene therapy applications of naked DNA constructs for genetic disorders have been limited because of lack of permanent transgene expression. This limitation, however, can be overcome by the Sleeping Beauty (SB) transposable element, which can achieve permanent transgene expression through genomic integration from plasmid DNA. To date, only one example of an in vivo gene therapy application of this system has been reported. In this report, we have further defined the activity of the SB transposon in vivo by analyzing the expression and integration of a fumarylacetoacetate hydrolase (FAH) transposon in FAH-deficient mice. In this model, stably corrected FAH+ hepatocytes are clonally selected and stable integration events can therefore be quantified and characterized at the molecular level. Herein, we demonstrate that SB-transposon-transfected hepatocytes can support significant repopulation of the liver, resulting in long-lasting correction of the FAH-deficiency phenotype. A single, combined injection of an FAH-expressing transposon plasmid and a transposase expression construct resulted in stable FAH expression in ∼1% of transfected hepatocytes. The average transposon copy number was determined to be ∼1/diploid genome and expression was not silenced during serial transplantation. Molecular analysis indicated that high-efficiency DNA-mediated transposition into the mouse genome was strictly dependent on the expression of wild-type transposase.

Original languageEnglish (US)
Pages (from-to)759-769
Number of pages11
JournalMolecular Therapy
Volume6
Issue number6
DOIs
StatePublished - Dec 1 2002

    Fingerprint

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery

Cite this

Montini, E., Held, P. K., Noll, M., Morcinek, N., Al-Dhalimy, M., Finegold, M., Yant, S. R., Kay, M. A., & Grompe, M. (2002). In vivo correction of murine tyrosinemia type I by DNA-mediated transposition. Molecular Therapy, 6(6), 759-769. https://doi.org/10.1006/mthe.2002.0812